Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Lintuzumab Bi-213

Next Previous
Drug Profile

Lintuzumab Bi-213

Alternative Names: Anti-CD33 monoclonal antibody M195 Bi-213; Bi213 MOAB M195; Bi213 monoclonal antibody M195; Bismab-A; Bismuth-213 HuM195; Bismuth-213 lintuzumab; Bismuth-213-labelled HuM195; HuM195-Bi-213; Lintuzumab bismuth-213; Monoclonal antibody M195 Bi-213 conjugate; Monoclonal antibody M195 bismuth-213; SMART M195 bismuth-213

Latest Information Update: 24 Apr 2019

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator PDL BioPharma
  • Developer Actinium Pharmaceuticals
  • Class Antineoplastics; Drug conjugates; Immunoconjugates; Monoclonal antibodies; Radiopharmaceuticals
  • Mechanism of Action CD33 antigen inhibitors; Ionising radiation emitters
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Discontinued Acute myeloid leukaemia

Most Recent Events

  • 17 Apr 2019 Actinium Pharmaceuticals plans a phase I trial for Acute myeloid leukaemia
  • 17 Jun 2013 Discontinued - Phase-I/II for Acute myeloid leukaemia in USA (IV)
  • 13 Jun 2012 Clinical development is ongoing in USA

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top